MedTrace Logo

Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus

NCT00603031 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2011-01-21

No results posted yet for this study

Summary

study hypothesis: treatment with GLP-1 and/or GIP is able to potentiate the maximal stimulated insulin secretion even in c-peptide negative type-1 diabetic patients classified as having no residual beta cell function left.

Conditions

  • Type-1 Diabetes Mellitus

Interventions

OTHER

glucagon like peptide -1

continuous infusion 1,2 pmol pr. kg pr minute at 120 minutes

OTHER

NaCl

infusion with NaCl for 120 minutes as placebo-arm

OTHER

glucose dependent insulinotropic polypeptide

continuous infusion with GIP-1 (3,6pmol/kg/min) at 120 minutes.

Sponsors & Collaborators

  • Hvidovre University Hospital

    lead OTHER

Principal Investigators

  • Urd Kielgast, MD · unafilliated

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00603031 on ClinicalTrials.gov